<VariationArchive VariationID="12847" VariationName="NM_003126.4(SPTA1):c.460_462dup (p.Leu155dup)" VariationType="Duplication" Accession="VCV000012847" Version="44" RecordType="classified" NumberOfSubmissions="12" NumberOfSubmitters="12" DateLastUpdated="2024-07-29" DateCreated="2018-04-02" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="27886" VariationID="12847">
      <GeneList>
        <Gene Symbol="SPTA1" FullName="spectrin alpha, erythrocytic 1" GeneID="6708" HGNC_ID="HGNC:11272" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q23.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="158610704" stop="158686715" display_start="158610704" display_stop="158686715" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="158580495" stop="158656505" display_start="158580495" display_stop="158656505" Strand="-" />
          </Location>
          <OMIM>182860</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_003126.4(SPTA1):c.460_462dup (p.Leu155dup)</Name>
      <CanonicalSPDI>NC_000001.11:158681595:CAAC:CAACAAC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>1q23.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="158681595" stop="158681596" display_start="158681595" display_stop="158681596" variantLength="3" positionVCF="158681595" referenceAlleleVCF="G" alternateAlleleVCF="GCAA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="158651385" stop="158651386" display_start="158651385" display_stop="158651386" variantLength="3" positionVCF="158651385" referenceAlleleVCF="G" alternateAlleleVCF="GCAA" />
      </Location>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1131" sequenceAccession="LRG_1131" change="g.10119_10121dup">
            <Expression>LRG_1131:g.10119_10121dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="protein">
          <ProteinExpression sequenceAccessionVersion="NP_003117.2" sequenceAccession="NP_003117" sequenceVersion="2" change="p.Leu154dup">
            <Expression>NP_003117.2:p.Leu154dup</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.158651387_158651389dup" Assembly="GRCh37">
            <Expression>NC_000001.10:g.158651387_158651389dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.158681597_158681599dup" Assembly="GRCh38">
            <Expression>NC_000001.11:g.158681597_158681599dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011474.1" sequenceAccession="NG_011474" sequenceVersion="1" change="g.10119_10121dup">
            <Expression>NG_011474.1:g.10119_10121dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003126.4" sequenceAccession="NM_003126" sequenceVersion="4" change="c.460_462dup" MANESelect="true">
            <Expression>NM_003126.4:c.460_462dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_003117.2" sequenceAccession="NP_003117" sequenceVersion="2" change="p.Leu155dup">
            <Expression>NP_003117.2:p.Leu155dup</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003126.2" sequenceAccession="NM_003126" sequenceVersion="2" change="c.460_462dupTTG">
            <Expression>NM_003126.2:c.460_462dupTTG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA213176" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="182860.0003" DB="OMIM" />
        <XRef Type="rs" ID="757679761" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003126.4(SPTA1):c.460_462dup (p.Leu155dup) AND Elliptocytosis 2" Accession="RCV000013700" Version="31">
        <ClassifiedConditionList TraitSetID="3500">
          <ClassifiedCondition DB="MedGen" ID="C1851741">Elliptocytosis 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-03-25" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003126.4(SPTA1):c.460_462dup (p.Leu155dup) AND not provided" Accession="RCV000598724" Version="44">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-07" SubmissionCount="7">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003126.4(SPTA1):c.460_462dup (p.Leu155dup) AND Pyropoikilocytosis, hereditary" Accession="RCV001336016" Version="9">
        <ClassifiedConditionList TraitSetID="3493">
          <ClassifiedCondition DB="MedGen" ID="C0520739">Pyropoikilocytosis, hereditary</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-10-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-03-25" NumberOfSubmissions="12" NumberOfSubmitters="12" DateCreated="2018-04-02" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1642244</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2567189</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27667160</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2794061</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30393954</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3597773</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3922449</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">4027386</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8434258</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8790144</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8857939</ID>
        </Citation>
        <DescriptionHistory Dated="2021-03-22">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2018-05-29">
          <Description>Pathogenic/Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2018-04-02">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3500" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1588" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ELLIPTOCYTOSIS, RHESUS-UNLINKED TYPE</ElementValue>
                <XRef Type="MIM" ID="130600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Elliptocytosis 2</ElementValue>
                <XRef ID="319613" DB="GeneTests" />
                <XRef ID="Elliptocytosis+2/8304" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007533" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">EL2</ElementValue>
                <XRef Type="MIM" ID="130600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15064" />
                <XRef ID="15064" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="288" DB="Orphanet" />
              <XRef ID="C1851741" DB="MedGen" />
              <XRef ID="MONDO:0007533" DB="MONDO" />
              <XRef Type="MIM" ID="130600" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3493" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5841" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pyropoikilocytosis</ElementValue>
                <XRef ID="HP:0004839" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pyropoikilocytosis, hereditary</ElementValue>
                <XRef ID="MONDO:0009948" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HPP</ElementValue>
                <XRef Type="MIM" ID="266140" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="4619" />
                <XRef ID="4619" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000522279" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522331" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528390" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <XRef ID="98867" DB="Orphanet" />
              <XRef ID="C0520739" DB="MedGen" />
              <XRef ID="MONDO:0009948" DB="MONDO" />
              <XRef Type="MIM" ID="266140" DB="OMIM" />
              <XRef Type="primary" ID="HP:0004839" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0004805" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="33947" SubmissionDate="2018-11-07" DateLastUpdated="2018-11-09" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="182860.0003_ELLIPTOCYTOSIS 2" title="SPTA1, 3-BP INS, LEU154DUP_ELLIPTOCYTOSIS 2" />
        <ClinVarAccession Accession="SCV000033947" DateUpdated="2018-11-09" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1992-08-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Marchesi et al. (1987) and Sahr et al. (1989) stated that the duplication occurred after leu148, but it was later found to occur after leu154. For a time the numbering system used for SPTA1 was based on a sequence that lacked the first 6 residues.</Attribute>
              <Citation>
                <ID Source="PubMed">3597773</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">2794061</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">This mutation has also been referred to as the alpha(I-65) mutation. In 2 American black patients with elliptocytosis (EL2; 130600), Marchesi et al. (1987) and Sahr et al. (1989) found insertion of an extra leucine residue after leucine-148. Roux et al. (1989) identified the molecular defect in 5 unrelated families in North Africa (Algeria) with the alpha-spectrin form of hereditary elliptocytosis. This form of elliptocytosis is associated with an abnormal 65-kD alpha-I peptide (rather than the normal 80-kD) following limited trypsin digestion of whole spectrin. The authors identified an extra leucine codon (TTG) between codons 147 and 149 in exon 4, the coding sequence becoming CAG TTG TTG CTG instead of CAG TTG CTG. The studies of Lecomte et al. (1988) indicated a high prevalence of hereditary elliptocytosis due to this mutation in populations of west Africa as well as in black people living in North America.</Attribute>
              <Citation>
                <ID Source="PubMed">3597773</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">2794061</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">2567189</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">3922449</ID>
              </Citation>
              <XRef DB="OMIM" ID="130600" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Boulanger et al. (1992) described fast screening methods for detection of this and the L260P mutation (182860.0001); the findings will be useful in studying the relationship between malaria resistance and the LEU154DUP mutation. Del Giudice et al. (1992) reported the same mutation in 2 women from southern Italy, Campania and Sicily; however, the associated haplotype was the same as that encountered in African and American blacks and in North Africans. It is assumed that the mutation was introduced from North Africa across the Sicilian channel and ultimately originated from the Benin-Togo area. This was the same migratory pathway followed by the Benin type hemoglobin S allele, which is also present in southern Italy.</Attribute>
              <Citation>
                <ID Source="PubMed">1642244</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">8434258</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <Name>SPTA1, 3-BP INS, LEU154DUP</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">3-BP INS, LEU154DUP</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="182860.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">ELLIPTOCYTOSIS 2</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3004506" SubmissionDate="2021-03-05" DateLastUpdated="2021-03-22" DateCreated="2021-03-22">
        <ClinVarSubmissionID localKey="NM_003126.2:c.460_462dupTTG|OMIM:266140" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001529291" DateUpdated="2021-03-22" DateCreated="2021-03-22" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-10-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">2567189</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8857939</ID>
          </Citation>
          <Comment>This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. Heterozygous p.L154dup has been previously reported in patients with Sp alpha I/65 hereditary elliptocytosis [PMID 2567189, 8857939]</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>paternal</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.2:c.460_462dupTTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="266140" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9201740</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4891319" SubmissionDate="2022-04-19" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_003126.2:c.460_462dupTTG|MedGen:C1851741" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002500695" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8857939</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">4027386</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">3597773</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27667160</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30393954</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2567189</ID>
          </Citation>
          <Comment>Variant summary: SPTA1 c.460_462dupTTG (p.Leu155dup) results in an in-frame duplication that is predicted to duplicate 1 amino acid into the encoded protein. The variant allele was found at a frequency of 7.6e-05 in 249160 control chromosomes, predominantly at a frequency of 0.0011 within the African or African-American subpopulation in the gnomAD database. c.460_462dupTTG (also described as Sp alpha[I/65] and as dupL154) has been reported in the literature in multiple heterozygous individuals, particularly of African descent, affected with hereditary elliptocytosis (e.g. Lawler_1985, Marchesi_1987, Roux_1989, Glele-Kakai_1996, Niss_2016) and in some compound heterozygous individuals affected with hereditary pyropoikilocytosis (e.g. Niss_2016). These data indicate that the variant is very likely to be associated with disease. Experimental evidence revealed a decrease of the alpha l domain of spectrin and presence of an atypical peptide and also, impaired ability to undergo self association to form tetramers and higher oligomers (Lawler_1985, Marchesi_1987). Five ClinVar submitters (evaluation after 2014) cite the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.2:c.460_462dupTTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1851741" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11350627</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5468866" SubmissionDate="2022-12-30" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="A18816|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002817230" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Athena Diagnostics" OrgID="1012" OrganizationCategory="laboratory" OrgAbbreviation="ADX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>This variant, also referred to as alpha I-65, is enriched in individuals with hereditary elliptocytosis (HE) as compared to the general population (PMID: 8857939, 2567189, 30393954, 32623341). The clinical presentation of HE in individuals who have this variant in the heterozygous sate is typically characterized by mild hemolytic anemia and abnormally-shaped red blood cells. The clinical presentation is more severe when this variant is compound heterozygous with a pathogenic SPTA1 variant. This variant has also been reported to be a modifier of sickle cell anemia (PMID: 2567189, 30393954, 32623341). The frequency of this variant in the general population is uninformative but consistent with pathogenicity (http://gnomad.broadinstitute.org).This observation is not an independent occurrence and has been identified in the same individual by RCIGM, the other laboratory participating in the GEMINI study.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Athena Diagnostics Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.2:c.460_462dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12495508</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1390391" SubmissionDate="2023-08-02" DateLastUpdated="2023-08-05" DateCreated="2018-04-02">
        <ClinVarSubmissionID localKey="GDXSV:282198" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000710385" DateUpdated="2023-08-05" DateCreated="2018-04-02" Type="SCV" Version="5" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Comment>Published functional studies on red blood cells extracted from patients with hereditary elliptocytosis (HE) who harbor the c.460_462dupTTG variant, show increased spectrum dimers as compared to wild type red blood cells, suggesting the variant causes a structural defect in the spectrin molecule affecting tetramer formation (Lawler et al., 1985); In-frame duplication of 1 amino acid in a non-repeat region; Also known as alpha I-65 or L148dup; This variant is associated with the following publications: (PMID: 2567189, 3597773, 2794061, 1353056, 27667160, 8857939, 30393954, 31040790, 34426522, 31589614, 32623341, 34889366, 34553410, 33074480, 34201899, 4027386)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:1890579</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.2:c.460_462dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_123_20220810054204</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_208_20230802054202</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_57_20210930044205</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3960603" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="7679e347c1ca20d0cd861ab3a1e77ad7f054e948d3bdebacd7bedf1baaddad96|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002023635" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" OrgAbbreviation="PKIG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.4:c.460_462dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4015383" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2022-01-08">
        <ClinVarSubmissionID localKey="39053|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002049268" DateUpdated="2024-02-20" DateCreated="2022-01-08" Type="SCV" Version="6" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The SPTA1 c.460_462dup, p.Leu155dup variant (rs757679761), also known as alpha(I-65), is reported in the literature multiple related and unrelated individuals and families, primarily of African descent, affected with hereditary elliptocytosis, although with variable clinical severity (del Giudice et al., 1992; Garbarz et al., 1986; Marchesi et al., 1987; Niss et al., 2016; Qualtieri et al., 1995; Roux et al., 1989; Sahr et al., 1989). This variant has also been reported in trans (on opposite chromosomes) from the alpha-LELY allele in two individuals affected with hereditary pyropoikilocytosis (Niss et al., 2016). In vitro functional analyses demonstrate impaired SPTA1 oligomer formation (Marchesi et al., 1987). This variant is reported as likely pathogenic by one laboratory in ClinVar (Variation ID: 12847). This variant is found predominantly in the African population with an overall allele frequency of 0.095% (23/24192 alleles, including no homozygotes) in the Genome Aggregation Database. This variant inserts a single leucine residue leaving the rest of the protein in-frame. Based on available information, this variant is considered to be likely pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.158651387_158651389dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
          <SubmissionName>May 2022</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8985164" SubmissionDate="2024-03-25" DateLastUpdated="2024-04-06" DateCreated="2024-03-30">
        <ClinVarSubmissionID localKey="NM_003126.4:c.460_462dup|OMIM:130600" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004805265" DateUpdated="2024-04-06" DateCreated="2024-03-30" Type="SCV" Version="2" SubmitterName="Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center" OrgID="508075" OrganizationCategory="other" OrgAbbreviation="CGM_KFSHRC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.4:c.460_462dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="130600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14337675</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7701713" SubmissionDate="2023-11-13" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="NM_003126.4:c.460_462dup|OMIM:130600" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004121694" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="Molecular Genetics and NGS Laboratory, Hospital Fundacion Valle Del Lili" OrgID="509060" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Latin</Ethnicity>
              <GeographicOrigin>Colombia</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_003126.4:exon 4</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Leu155dup</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.4:c.460_462dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="130600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13969911</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3376042" SubmissionDate="2024-01-05" DateLastUpdated="2024-01-26" DateCreated="2021-06-15">
        <ClinVarSubmissionID localKey="376257|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001715609" DateUpdated="2024-01-26" DateCreated="2021-06-15" Type="SCV" Version="3" SubmitterName="Mayo Clinic Laboratories, Mayo Clinic" OrgID="500068" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">2567189</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8790144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8857939</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="37" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_003126.4:exon 4</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Leu155dup</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003126.4:c.460_462dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13399149</SubmissionName>
          <SubmissionName>SUB14137495</SubmissionName>
          <SubmissionName>SUB9741791</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4232080" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="4820278|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002214445" DateUpdated="2024-02-14" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">1642244</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2567189</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2794061</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">3922449</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8790144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8857939</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30393954</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">3922449</ID>
          </Citation>
          <Comment>This variant, c.460_462dup, results in the insertion of 1 amino acid(s) of the SPTA1 protein (p.Leu155dup), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs757679761, gnomAD 0.09%). This variant has been observed in individuals with autosomal dominant hereditary elliptocytosis and autosomal recessive hereditary pyropoikilocytosis (PMID: 1642244, 2567189, 2794061, 3922449, 8790144, 8857939, 30393954). It has also been observed to segregate with disease in related individuals. This variant is also known as dupL154 and duplication of codon 154. ClinVar contains an entry for this variant (Variation ID: 12847). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects SPTA1 function (PMID: 3922449). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.158651385_158651386insCAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7506332" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2023-07-16">
        <ClinVarSubmissionID localKey="130643|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004009893" DateUpdated="2024-07-15" DateCreated="2023-07-16" Type="SCV" Version="9" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>SPTA1: PM3:Very Strong, PM1, PM2, PP1:Moderate, PS3:Moderate, PM4:Supporting, PP4</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SPTA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="1" alternateAllele="GCAA" referenceAllele="G" start="158651385" stop="158651385" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5468866" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4232080" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1390391" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3376042" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4891319" TraitType="Disease" MappingType="XRef" MappingValue="C1851741" MappingRef="MedGen">
        <MedGen CUI="C1851741" Name="Elliptocytosis 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7701713" TraitType="Disease" MappingType="XRef" MappingValue="130600" MappingRef="OMIM">
        <MedGen CUI="C1851741" Name="Elliptocytosis 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3960603" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3004506" TraitType="Disease" MappingType="XRef" MappingValue="266140" MappingRef="OMIM">
        <MedGen CUI="C0520739" Name="Pyropoikilocytosis, hereditary" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4015383" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="33947" TraitType="Disease" MappingType="Name" MappingValue="ELLIPTOCYTOSIS 2" MappingRef="Preferred">
        <MedGen CUI="C1851741" Name="Elliptocytosis 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7506332" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8985164" TraitType="Disease" MappingType="XRef" MappingValue="130600" MappingRef="OMIM">
        <MedGen CUI="C1851741" Name="Elliptocytosis 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

